Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer * Advanced disease (stage IIIB disease \[malignant pleural or pericardial effusion seen on CT or Chest X-ray, any N, M0\] or stage IV disease \[Any T, any N, M1: distant metastases\]) that is primary or recurrent * Measurable disease according to the RECIST criteria * ECOG Performance Status 0 or 1 * Adequate organ function, as evidenced by ALL the following * Absolute neutrophil count (ANC) ≥ 1500/mm³ and platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9 gm/dL * Total bilirubin ≤ 1 X institutional ULN; if patient has Gilbert's disease, then patient must have isolated hyperbilirubinemia (e.g. no other liver function test abnormality), with maximum bilirubin ≤ 2 X institutional ULN. * AST, ALT and alkaline phosphatase (Alk Phos) must be ≤ 1.5 ULN * Creatinine ≤ 1.5 X institutional ULN or calculated creatinine clearance ≥ 60 ml/min * Potassium between 4 mEq/L and institutional ULN (supplementation may be used), * Calcium (ionized or adjusted for albumin)within institutional normal limits * Magnesium within institutional normal limits (supplementation may be used) * No prior cytotoxic chemotherapy or targeted therapy for advanced or metastatic disease (Prior adjuvant therapy for lung cancer allowed if completed \> 1 year prior to registration) * Able to take oral medication Exclusion Criteria: * Myocardial infarction, superior vena caval syndrome, NYHA classification of heart disease ≥ 2 within the 3 months prior to entry * History of an uncontrolled or recurrent ventricular, supraventricular or nodal arrhythmia that requires treatment * Hypertension not controlled by medication * Peripheral or sensory neuropathy \> grade 1 * Known hypersensitivity to carboplatin or docetaxel * Active infection